Novan Interest Expense 2011-2026 | NOVN

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Novan

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.45 M	-746 K	-	2 K	1.05 M	1.05 M	2 K	1 K	701 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.45 M	-746 K	438 K

Quarterly Interest Expense Novan

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
277 K	-	635 K	608 K	132 K	-	-5 K	73 K	-	-	-	-	8 K	1 K	-	1 K	-	262 K	262 K	261 K	262 K	-	262 K	262 K	262 K	77 K	7 K	31 K	12 K	18 K	30 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
635 K	-5 K	170 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Alterity Therapeutics Limited ATHE	2.28 K	$ 4.3	8.4 %	$ 10.3 B	Australia
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Akari Therapeutics, Plc AKTX	100 K	$ 5.26	2.7 %	$ 354 B	Britain
Aligos Therapeutics ALGS	2.2 M	$ 6.7	-12.53 %	$ 66.2 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Alnylam Pharmaceuticals ALNY	5.2 M	$ 315.2	-1.54 %	$ 41.3 B	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 22.46	2.98 %	$ 1.05 B	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
BioNTech SE BNTX	14.2 M	$ 104.56	2.39 %	$ 27.2 B	Germany
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.08	-	$ 5.07 M	Israel
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
BioXcel Therapeutics BTAI	-3.52 M	$ 1.19	11.23 %	$ 14.5 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	58 K	$ 1.39	2.96 %	$ 357 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.35	2.0 %	$ 465 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 24.45	1.07 %	$ 3.11 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Cabaletta Bio CABA	2 M	$ 3.34	-5.26 %	$ 336 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.64	1.86 %	$ 436 M	Britain
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Celldex Therapeutics CLDX	927 K	$ 35.15	3.81 %	$ 2.33 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Cidara Therapeutics CDTX	5.81 M	-	-	$ 1.41 B	USA
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA